HuGEMM™ and HuCELL™

CrownBio
CONNECTING SCIENCE TO PATIENTS

## Humanized drug target models for immunotherapy evaluation

Discover the benefits that unique humanized target models featuring functional immune systems bring to immunotherapy drug development programs.

HuGEMM and HuCELL models allow the rapid evaluation of human-specific biological therapies *in vivo*, with:

- HuGEMM mouse models with stable humanized drug target expression, including PD-1, PD-L1, and CTLA-4.
- HuCELL syngeneic tumor cells with stable humanized ligand expression, e.g. PD-L1.
- Key checkpoint target platforms developed, including double knock-in models for combination ICI assessment, with many more under development.

Choose HuGEMM and HuCELL humanized drug target models to:

- Interrogate the effectiveness of human-specific checkpoint inhibitors alone, or in combination with therapeutics potentiating the tumor immune microenvironment.
- Evaluate your immunotherapies within a competent murine immune system featuring relevant human-specific targets.
- Combine HuGEMM and HuCELL models for a fully humanized receptor-ligand complex.
- Assess target engagement and pharmacodynamics of your immuno-oncology agents.

Humanized
Immunotherapy
Target

Engrafted with
syngeneic tumor cells

HuGEMM™
Humanized Target
Tumor Bearing Model

Humanized
Immunotherapy
Target

HuCELL™
Humanized Target
Tumor Cells